Browsing by Subject "prostate cancer"
Now showing items 1-6 of 6
-
Development of SIRT1 siRNA-carrying liposomes for treatment of prostate cancer
(2020)Sirtuin 1 (SIRT1) is a histone deacetylase (HDAC) from Sirtuin family and high expression of it induces activation of DNA repairing factors eventually leading either tumor suppression or tumor development in cellular ... -
Dual targeting of tumour cells and host endothelial cells by novel microtubule-targeting agents, pyrrolo-1,5-benzoxazepines.
(Springer, 2010)Advanced hormone-refractory prostate cancer is associated with poor prognosis and limited treatment options. Members of the pyrrolo-1,5-benzoxazepine (PBOX) family of compounds exhibit anti-cancer properties in cancer cell ... -
Endosomal gene expression: a new indicator for prostate cancer patient prognosis?
(2015)Prostate cancer continues to be a major cause of morbidity and mortality in men, but a method for accurate prognosis in these patients is yet to be developed. The recent discovery of altered endosomal biogenesis in prostate ... -
The HIF-1alpha C1772T polymorphism may be associated with susceptibility to clinically localised prostate cancer but not with elevated expression of hypoxic biomarkers.
(2009)We investigated the role of the C1772T polymorphisms in exon 12 of the Hypoxia-inducible factor-1 alpha (HIF-1alpha) gene C1772T genotype in prostate cancer (PCa) and amplification of the hypoxic response. We identified ... -
miR-34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression.
(2014)BACKGROUND Docetaxel-resistance limits successful treatment of castration resistant prostate cancer. We previously demonstrated that extracellular vesicles (exosomes) may play a role in regulating docetaxel resistance. ... -
Targeting the prostate cancer metabolome with novel trojan horse compounds.
(Trinity College Dublin. School of Medicine. Discipline of Histopathology, 2023)Prostate cancer (PCa) is the second most common cancer diagnosed in males worldwide, and the incidence of this disease is predicted to double globally by 2030. In Ireland, PCa accounts for nearly 16% of all invasive cancers ...